Wolverine Asset Management LLC Neurocrine Biosciences Inc Transaction History

Wolverine Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 08, 2023	BUY	$94.11 - $123.02 $1,411 - $1,845	15 New	15 $1,000
Q3 2021 Nov 12, 2021	SELL	$86.18 - $99.03 $171,842 - $197,465	-1,994 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $160,437 - $183,472	1,794 Added 897.0%	1,994 $194,000
Q1 2021 May 13, 2021	SELL	$87.57 - $119.4 $18,827 - $25,671	-215 Reduced 51.81%	200 $19,000
Q4 2020 Feb 12, 2021	BUY	$86.91 - $108.33 $36,067 - $44,956	415 New	415 $39,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $1,442 - $2,027	-15 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$85.09 - $130.36 $1,276 - $1,955	15 New	15 $1,000
Q1 2019 May 15, 2019	SELL	$69.31 - $91.53 $168,561 - $222,600	-2,432 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $166,154 - $302,443	2,432 New	2,432 $173,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Wolverine Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Asset Management LLC with notifications on news.